You just read:

Amygdala Neurosciences Initiates Phase 1b Clinical Study of ANS-6637, the First-In-Class Selective ALDH2 Inhibitor in Development as a Treatment for Substance Use Disorder

News provided by

Amygdala Neurosciences Inc.

Aug 01, 2017, 10:53 ET